Breaking news

Why the UAE Is Becoming A Premier Destination For Medical Tourism

With a commitment to enhancing its healthcare offerings, the UAE has positioned itself as a leader in medical tourism, catering to a growing global demand. As countries focus on improving the health of their populations, the UAE stands out for its strategic investments in both healthcare infrastructure and its appeal to medical tourists.

According to Statista, the global medical tourism market was valued at $47 billion in 2024, with projections indicating it could exceed $111 billion by 2029. The UAE is setting the bar high, with innovative initiatives such as specialized portals for health tourists and streamlined entry processes for medical visitors.

Tailored Portals And Seamless Experiences

Abu Dhabi and Dubai have launched dedicated online platforms that streamline the process for medical tourists. These portals offer a range of services, including healthcare provider contact information, appointment bookings, hotel reservations, and local transportation. Dubai Health Authority (DHA) introduced the Dubai Health Experience (DXH) brand in 2016, aimed at making the city a global leader in health tourism. The platform offers a curated selection of top-tier treatments in fields such as dentistry, fertility, ophthalmology, and cosmetic surgery.

Meanwhile, in 2018, Abu Dhabi’s Department of Health (DoH) rolled out its own e-portal, showcasing a network of over 40 healthcare facilities that meet the stringent quality standards of the DoH’s JAWDA program. Visitors can explore nearly 300 treatment packages across specialties ranging from routine check-ups to complex surgeries.

Simplified Access With Specialized Permits

To further attract international patients, the UAE offers specialized entry permits for medical tourists and their companions. These permits, which can be single or multiple entries, are sponsored by medical institutions and processed by relevant authorities in the country. Dubai Healthcare City also introduced a new medical visa in January 2024, allowing treatment centers to apply for permits on behalf of patients for stays of up to six months. This move bolsters Dubai’s reputation as a medical tourism hotspot.

The city welcomed 674,000 medical tourists in 2022, generating $270 million in revenue. Wellness tourism is also booming in the UAE, with visitors spending $5.4 billion in 2022—almost double the amount spent in 2020.

Innovation At The Forefront

The UAE’s innovative spirit continues to propel its rise as a medical tourism hub. In 2024, HealthStay.io, the world’s first AI-powered medical tourism solution, launched in partnership with Dubai Health Experience. This startup, part of the Mohammed Bin Rashid Innovation Fund’s Accelerator Program, uses artificial intelligence to automate the medical tourism journey, including selecting treatments and booking appointments.

“The launch of HealthStay.io is a direct result of the support from DXH and DHA, helping us transform Dubai into a global healthcare tourism leader,” said Ruairi Tubrid, co-founder of HealthStay.io. Fatima Yousif Alnaqbi, MBRIF representative, emphasized the importance of accelerator programs in supporting innovative solutions that elevate the UAE’s standing as a center of excellence in healthcare.

Government Commitment To Healthcare Excellence

The UAE’s rapid growth in medical tourism is rooted in its consistent focus on healthcare improvement. Key strategies such as the Emirates Health Services Innovation Strategy 2023-2026 and the National Strategy for Wellbeing 2031 aim to enhance residents’ quality of life and elevate the nation’s healthcare offerings.

Compared to its Gulf Cooperation Council (GCC) counterparts, the UAE leads in healthcare expenditure growth. Projections from Alpen Capital estimate that healthcare spending will reach $30.7 billion by 2027, reflecting the nation’s ongoing dedication to strengthening its healthcare infrastructure. As a result, the UAE continues to attract international patients seeking top-tier medical services.

China’s Humanoid Robot Boom Faces A Bigger Question: Can These Machines Make Money?

Unitree’s $9 Billion Bet On The Future Of Robotics

China’s humanoid robotics industry is attracting huge investor interest, but as Unitree Robotics prepares for its public debut, questions are growing over whether its robots can move beyond impressive acrobatics and become commercially viable tools.

The Hangzhou-based startup priced its IPO at 150.8 yuan ($22.4) per share, raising $900 million and valuing the company at 61 billion yuan, or about $9 billion. The offering attracted record retail demand on Shanghai’s STAR Market, with the online tranche oversubscribed more than 5,000 times and a winning rate of just 0.018%. Strategic investors included AI startup DeepSeek.

A Unitree-linked pre-IPO perpetual contract was trading at roughly four times the IPO price on Friday, highlighting the speculative interest surrounding the company.

Unitree is known for robots capable of kung fu kicks, backflips and recovering from falls. Yet analysts question whether the technology is ready for large-scale commercial use. “For these humanoid robots, to be honest, they’re fascinating. They can dance and all that, but I’ve never seen them doing any real housework,” said Hao Hong, managing partner of Lotus Asset Management.

In its prospectus, Unitree warned that mass adoption could take longer than expected because robotic hands are still not precise or durable enough for sustained use.

From Acrobatic Robots To Commercial Machines

Even advanced humanoid robots can currently perform only a limited number of tasks and typically operate for a few hours before recharging, according to Dominik Pross, an equity analyst at VP Bank. Most models run for up to four hours, while robots also need to be trained for individual tasks.

“Robots have to be specifically trained for each and every task entrusted to them, even the simplest,” Pross said.

More robotics listings are expected, with Unitree rivals AgiBot and Leju Robotics seeking listings in Hong Kong and Shenzhen. LimX Dynamics founder Will Zhang said last month that “listing is a must.”

China’s Cost Advantage

China’s manufacturing scale has helped it establish a leading position in robotics. Wood Mackenzie expects the global humanoid robot fleet to surpass 10 million units by 2035, while China already accounts for more than 70% of global industrial robot installations and nearly 90% of humanoids deployed last year.

Average humanoid robot prices fell 93% between 2020 and 2025 to $58,000. Unitree’s flagship G1 costs $16,000, while SemiAnalysis estimates that the company has cut the price of its G1 EDU model by more than 45% to $27,300, while maintaining a 67% gross margin.

Falling prices and government support are attracting investment, but analysts say it will take time to prove that humanoid robots can generate strong returns. Unitree’s revenue more than quadrupled last year, although adjusted first-quarter profit fell more than 52% as research and development and marketing spending increased. Nearly three-quarters of its humanoid revenue in the first nine months of 2025 came from research and education, highlighting the gap between demonstrations and widespread commercial use.

“Unlike many early-stage robotics companies, the Unitree story is backed by real revenue growth,” said Jeff Ko, chief analyst at CoinEx. Still, he noted that its $9 billion valuation, at more than 200 times last year’s earnings, reflects significant speculative interest.

Geopolitical Risks

Unitree’s IPO momentum has continued despite growing pressure on Chinese robotics companies. The U.S. moved last month to ban imports of foreign-made humanoid and four-legged robots, potentially exposing Unitree, which generated about 13% of its revenue from the U.S. last year.

Access to Nvidia hardware and software is another risk, as Chinese robotics companies rely on the technology to power their systems. “Chinese robot producers are not yet in a position to do without Western components completely,” Pross said.

China’s control over rare earths used in robot actuators and motors could nevertheless give its manufacturers an advantage, according to Bernstein analyst Dien Wang.

The Bigger Robotics Opportunity

The potential market is attracting major players, including Tesla, whose CEO Elon Musk is expanding production plans for Optimus humanoid robots. At the same time, some researchers argue that the future of robotics will not be limited to humanoids: quadruped and purpose-built robots can be cheaper and more reliable for repetitive industrial tasks, while humanoids may be better suited to unpredictable environments.

For Unitree, the challenge is no longer proving that its robots can perform impressive tricks. It is proving that they can do enough useful work to justify a $9 billion valuation.

eCredo
Uol
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter